The growing role of precision and personalized medicine for cancer treatment

被引:382
作者
Krzyszczyk, Paulina [1 ]
Acevedo, Alison [1 ]
Davidoff, Erika J. [1 ]
Timmins, Lauren M. [1 ]
Marrero-Berrios, Ileana [1 ]
Patel, Misaal [1 ]
White, Corina [1 ]
Lowe, Christopher [1 ]
Sherba, Joseph J. [1 ]
Hartmanshenn, Clara [2 ]
O'Neill, Kate M. [1 ]
Balter, Max L. [1 ]
Fritz, Zachary R. [1 ]
Androulakis, Ioannis P. [1 ,2 ]
Schloss, Rene S. [1 ]
Yarmush, Martin L. [1 ,2 ]
机构
[1] Rutgers State Univ, Dept Biomed Engn, 599 Taylor Rd, Piscataway, NJ 08854 USA
[2] Rutgers State Univ, Dept Chem & Biochem Engn, 98 Brett Rd, Piscataway, NJ 08854 USA
来源
TECHNOLOGY | 2018年 / 6卷 / 3-4期
关键词
Cancer; Cancer Treatment; Precision Medicine; Personalized Medicine;
D O I
10.1142/S2339547818300020
中图分类号
T [工业技术];
学科分类号
08 ;
摘要
Cancer is a devastating disease that takes the lives of hundreds of thousands of people every year. Due to disease heterogeneity, standard treatments, such as chemotherapy or radiation, are effective in only a subset of the patient population. Tumors can have different underlying genetic causes and may express different proteins in one patient versus another. This inherent variability of cancer lends itself to the growing field of precision and personalized medicine (PPM). There are many ongoing efforts to acquire PPM data in order to characterize molecular differences between tumors. Some PPM products are already available to link these differences to an effective drug. It is clear that PPM cancer treatments can result in immense patient benefits, and companies and regulatory agencies have begun to recognize this. However, broader changes to the healthcare and insurance systems must be addressed if PPM is to become part of standard cancer care.
引用
收藏
页码:79 / 100
页数:22
相关论文
共 192 条
[1]  
Agilent, HERC
[2]   Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].
Alizadeh, AA ;
Eisen, MB ;
Davis, RE ;
Ma, C ;
Lossos, IS ;
Rosenwald, A ;
Boldrick, JG ;
Sabet, H ;
Tran, T ;
Yu, X ;
Powell, JI ;
Yang, LM ;
Marti, GE ;
Moore, T ;
Hudson, J ;
Lu, LS ;
Lewis, DB ;
Tibshirani, R ;
Sherlock, G ;
Chan, WC ;
Greiner, TC ;
Weisenburger, DD ;
Armitage, JO ;
Warnke, R ;
Levy, R ;
Wilson, W ;
Grever, MR ;
Byrd, JC ;
Botstein, D ;
Brown, PO ;
Staudt, LM .
NATURE, 2000, 403 (6769) :503-511
[3]  
Almanfaluti M., 2018, MAJDOLIN
[4]   QIAGEN Therascreen KRAS RGQ Assay, QIAGEN KRAS Pyro Assay, and Dideoxy Sequencing for Clinical Laboratory Analysis of KRAS Mutations in Tumor Specimens [J].
Alqahtani, Qamra M. ;
Crowley, Ann ;
Rapp, Sharleen ;
Cushman-Vokoun, Allison M. .
LABORATORY MEDICINE, 2016, 47 (01) :30-38
[5]  
Amazon Web Services-Government Education & Nonprofi t Blog, CLOUD EN INN PERS ME
[6]  
[Anonymous], 2018, PREC MED
[7]  
[Anonymous], 2018, BIOL THER CANC
[8]   PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].
Ansell, Stephen M. ;
Lesokhin, Alexander M. ;
Borrello, Ivan ;
Halwani, Ahmad ;
Scott, Emma C. ;
Gutierrez, Martin ;
Schuster, Stephen J. ;
Millenson, Michael M. ;
Cattry, Deepika ;
Freeman, Gordon J. ;
Rodig, Scott J. ;
Chapuy, Bjoern ;
Ligon, Azra H. ;
Zhu, Lili ;
Grosso, Joseph F. ;
Kim, Su Young ;
Timmerman, John M. ;
Shipp, Margaret A. ;
Armand, Philippe .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319
[9]   Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].
Antonia, S. J. ;
Villegas, A. ;
Daniel, D. ;
Vicente, D. ;
Murakami, S. ;
Hui, R. ;
Yokoi, T. ;
Chiappori, A. ;
Lee, K. H. ;
de Wit, M. ;
Cho, B. C. ;
Bourhaba, M. ;
Quantin, X. ;
Tokito, T. ;
Mekhail, T. ;
Planchard, D. ;
Kim, Y. -C. ;
Karapetis, C. S. ;
Hiret, S. ;
Ostoros, G. ;
Kubota, K. ;
Gray, J. E. ;
Paz-Ares, L. ;
de Castro Carpeno, J. ;
Wadsworth, C. ;
Melillo, G. ;
Jiang, H. ;
Huang, Y. ;
Dennis, P. A. ;
Ozguroglu, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929
[10]  
Appendix E., 2011, PREC MED BUILD KNOWL, P124